Icure Pharmaceutical Incorporation
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides … Read more
Icure Pharmaceutical Incorporation (175250) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.055x
Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has a cash flow conversion efficiency ratio of -0.055x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.28 Billion) by net assets (₩59.43 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Icure Pharmaceutical Incorporation - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Icure Pharmaceutical Incorporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Icure Pharmaceutical Incorporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tung Ho Textile Co Ltd
TW:1414
|
0.013x |
|
Wattanapat Hospital Trang Public Company Limited
BK:WPH
|
0.047x |
|
Motisons Jewellers Ltd
NSE:MOTISONS
|
-0.124x |
|
Ray Sigorta AS
IS:RAYSG
|
-0.039x |
|
Tin Nghia Industrial Park Development JSC
VN:TIP
|
N/A |
|
Geodrill Limited
OTCQX:GEODF
|
0.108x |
|
Hi-Lai Foods Co Ltd
TWO:1268
|
0.092x |
|
Duksung Co Ltd
KO:004835
|
0.014x |
Annual Cash Flow Conversion Efficiency for Icure Pharmaceutical Incorporation (2015–2024)
The table below shows the annual cash flow conversion efficiency of Icure Pharmaceutical Incorporation from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩60.26 Billion | ₩-17.05 Billion | -0.283x | -24.75% |
| 2023-12-31 | ₩59.59 Billion | ₩-13.52 Billion | -0.227x | -80.30% |
| 2022-12-31 | ₩89.67 Billion | ₩-11.28 Billion | -0.126x | +54.07% |
| 2021-12-31 | ₩95.76 Billion | ₩-26.23 Billion | -0.274x | -147.68% |
| 2020-12-31 | ₩112.15 Billion | ₩-12.40 Billion | -0.111x | -81.49% |
| 2019-12-31 | ₩97.53 Billion | ₩-5.94 Billion | -0.061x | +29.34% |
| 2018-12-31 | ₩84.69 Billion | ₩-7.30 Billion | -0.086x | -234.63% |
| 2017-12-31 | ₩17.47 Billion | ₩1.12 Billion | 0.064x | +122.24% |
| 2016-12-31 | ₩16.94 Billion | ₩-4.88 Billion | -0.288x | -741.49% |
| 2015-12-31 | ₩5.96 Billion | ₩-204.05 Million | -0.034x | -- |